DR. PAUL W. DREW, DPT

Plain English
This study looked at how exposure to alcohol during development affects specific brain cells in mice, particularly focusing on the Purkinje cells and microglia in the cerebellum. The researchers found that alcohol exposure reduced the activity of Purkinje cells, while it did not significantly impact the immune cells (microglia) in the brain. This is important because it highlights that alcohol exposure can lead to lasting brain changes that may contribute to motor and coordination problems often seen in individuals with fetal alcohol spectrum disorders. Who this helps: Patients with fetal alcohol spectrum disorders and their families.

Plain English
This study looked at how long-term and binge drinking alcohol affects inflammation in the brains of mice, specifically in areas linked to movement and memory. The researchers found that alcohol increased harmful inflammation signs in the brain and that a drug called pioglitazone could reduce some of this inflammation. This matters because it shows potential ways to protect the brain from damage in people with alcohol use disorders. Who this helps: This helps patients with alcohol use disorders by offering another avenue for treatment.

Plain English
This study looked at how chronic and binge drinking affects the brain, particularly the cerebellum, in mice. It found that alcohol exposure led to significant changes in gene activity related to brain inflammation and cell function, with specific decreases in protective genes and increases in those linked to brain damage. This matters because understanding these changes helps explain how alcohol can harm brain health and function. Who this helps: This research benefits patients with alcohol use disorder by providing insights that could lead to better treatments.

Plain English
This study examined the effects of alcohol exposure on the brain development of mice, which serve as a model for human fetal alcohol spectrum disorders (FASD). Researchers found that just 1 or 2 days of alcohol exposure led to significant changes in the cerebellum, affecting cell functions related to the immune system and nerve cell health. Understanding these early changes is crucial because it can lead to new treatment options for children with FASD, a condition affecting 1-5% of school-aged kids in the U.S. Who this helps: This helps children affected by fetal alcohol spectrum disorders and the doctors treating them.

Plain English
Researchers studied how drinking alcohol during pregnancy affects certain brain cells in the cerebellum of developing mice. They found that exposure to alcohol in early development did not significantly change the shape or behavior of immune cells called microglia or their interactions with nearby nerve cells (Purkinje cells). This is important because it suggests that other factors may contribute to the brain problems seen in people with fetal alcohol spectrum disorders (FASD). Who this helps: This helps scientists and doctors working to understand and address the impacts of FASD.

Plain English
This study looked at how alcohol triggers inflammation in the brain, which may play a role in alcohol use disorder (AUD). Researchers found that in mice, drinking alcohol increased levels of certain inflammatory markers in the brain, particularly in those with working TLR4 and MyD88 pathways. Specifically, numbers showed that alcohol boosted the expression of inflammatory molecules in certain types of mice, while it had little effect on those lacking TLR4 or MyD88. Understanding this process is important because it helps clarify how alcohol can lead to brain inflammation, which may worsen AUD. Who this helps: This helps researchers and doctors working with patients struggling with alcohol use disorder.

Plain English
This study looked at how brain scans (MRI) can help predict future disability and cognitive decline in patients with multiple sclerosis (MS). Researchers analyzed information from 64 studies and found that brain imaging can moderately predict changes in disability and cognitive ability, with correlation values of 0.42 for disability and 0.47 for cognitive decline. These findings underscore the importance of using brain imaging to inform early interventions for better management of MS. Who this helps: This research benefits patients with multiple sclerosis and their doctors by improving understanding of their condition.

Plain English
This study looked at how alcohol exposure during pregnancy affects brain cells in developing babies, leading to fetal alcohol spectrum disorders (FASD). The researchers found that alcohol can activate certain brain support cells (microglia and astrocytes), which can cause inflammation and damage to the brain. This is important because it suggests that using anti-inflammatory treatments might help improve outcomes for those affected by FASD. Who this helps: This helps pregnant women with alcohol use issues and their babies.

Plain English
Researchers studied the effects of alcohol on brain inflammation in young mice that are similar to humans with fetal alcohol spectrum disorders (FASD). They found that inflammation in a specific brain area called the cerebellum continued for several days even after alcohol was stopped, indicating that timing for potential treatments is crucial. Additionally, the study identified changes in various immune molecules caused by alcohol, suggesting new targets for therapies aimed at helping those with FASD. Who this helps: This research benefits patients with fetal alcohol spectrum disorders and the doctors treating them.

Plain English
This study looked at how brain cells called astrocytes and microglia respond to a single exposure to alcohol during development in mice. The researchers found that while there weren't major changes in the shapes or protein levels of these cells, there were still some small effects that could lead to developmental issues later on. This is important because it helps us understand the biological impact of drinking during pregnancy and its potential link to lasting problems in kids with fetal alcohol spectrum disorders, which affect nearly 5% of U.S. births. Who this helps: This helps patients, particularly children affected by fetal alcohol spectrum disorders, and their families.

Plain English
The study looked at how exposure to alcohol during a critical period of brain development affects the expression of genes in two brain areas: the hippocampus and cerebellum. Researchers found that while alcohol generally increased genes linked to cell growth in both areas, the specific genes and pathways affected were quite different: the cerebellum showed changes related to cell division phases and a specific signaling pathway, while the hippocampus showed changes that impacted protein production and certain types of brain cells. This is important because it highlights how alcohol can harm brain development in unique ways depending on the brain region, which could help us understand the different neurobehavioral issues caused by fetal alcohol exposure. Who this helps: This helps researchers and doctors working with patients affected by fetal alcohol spectrum disorders.

Plain English
This study looked at how alcohol affects brain development in young mice, specifically focusing on an area called the hippocampus, which is important for learning and memory. Researchers found that alcohol led to increased inflammation and decreased the levels of important molecules for brain cell function and myelination, which is necessary for proper nerve signal transmission. These changes could harm cognitive abilities in individuals affected by fetal alcohol spectrum disorders (FASD), which are linked to alcohol exposure during pregnancy. Who this helps: This helps patients with fetal alcohol spectrum disorders and their families.

Plain English
This study looked at how alcohol affects the development of certain brain cells in young mice that model fetal alcohol spectrum disorders (FASD). Researchers found that alcohol exposure led to a significant reduction in the growth of important brain cells called oligodendrocytes, which are crucial for myelination—the process that allows nerve cells to communicate properly. This matters because poor myelination can lead to problems with thinking and movement in individuals with FASD. Who this helps: This research benefits patients with fetal alcohol spectrum disorders and could guide new treatments for them.

Plain English
Researchers studied how the drug pioglitazone could protect the brain from damage caused by binge drinking. In tests with rats, they found that pioglitazone reduced cell damage in brain areas affected by alcohol and improved cognitive abilities, like learning and memory. Specifically, it lowered harmful inflammatory signals and helped rats recover from learning difficulties caused by binge drinking. Who this helps: This helps young people who binge drink and are at risk of brain damage and cognitive issues.

Plain English
This study investigated how a protein called HuR influences the movement of certain immune cells, known as Th17 cells, in conditions like multiple sclerosis. Researchers found that when HuR was removed from mice, the Th17 cells had lower levels of a receptor called CCR6, which reduced their ability to migrate to the central nervous system, leading to less severe symptoms. This is important because it shows that targeting HuR could offer a new way to treat autoimmune diseases affecting the nervous system. Who this helps: This benefits patients with autoimmune diseases such as multiple sclerosis.

Plain English
This study looked at how alcohol exposure affects the brain and can cause inflammation, leading to problems for both toddlers with fetal alcohol spectrum disorder (FASD) and adults with alcohol use disorder (AUD). Researchers found that this inflammation could be a big factor in the health issues and behavioral problems linked to these disorders. They also explored possible treatments using specific molecules that could help reduce this inflammation and improve brain health. Who this helps: This benefits patients with fetal alcohol spectrum disorder and alcohol use disorder, as well as healthcare providers working with these individuals.

Plain English
This study looked at fetal alcohol spectrum disorders (FASD), which are caused by alcohol exposure during pregnancy and can severely affect brain development, leading to lasting cognitive and behavioral issues. Researchers found that alcohol triggers inflammation in the developing brain, and anti-inflammatory drugs called PPAR-γ agonists can help reduce this inflammation. This matters because finding effective treatments for FASD can greatly improve the quality of life for those affected. Who this helps: This helps patients with FASD and their families.

Plain English
This study looked at how the drug pioglitazone can help prevent brain damage caused by alcohol exposure during development in a mouse model for fetal alcohol spectrum disorders (FASD). The researchers found that alcohol increased harmful substances called cytokines and changed brain cells in ways that signal inflammation. Pioglitazone successfully blocked these harmful effects, bringing the levels of cytokines back to normal in the treated mice. This matters because it suggests that pioglitazone, and similar anti-inflammatory drugs, could be new treatment options to protect developing brains from alcohol-related damage. Who this helps: This helps patients with fetal alcohol spectrum disorders and their families.

Plain English
This study looked at how alcohol affects the immune response in the brains of young versus adult mice. The researchers found that alcohol increased certain immune markers in adult mice but not in adolescent mice, specifically increasing a chemokine called CCL2 in all brain areas studied and a cytokine known as IL-6 in the cerebellum. Notably, the immune response to alcohol was different between the age groups, which could help explain why younger and older individuals may be affected by alcohol differently in terms of brain health. Who this helps: This helps researchers and healthcare providers understand age-related differences in alcohol's impact on the brain, which can improve treatment and prevention strategies for alcohol-related issues.

Plain English
Researchers studied a compound called AS101 to see how it affects immune system cells that contribute to inflammation in a model of multiple sclerosis. They found that AS101 significantly reduced the production of harmful substances that drive inflammation, leading to a decrease in specific immune cells involved in the disease. For instance, it lowered levels of IL-17, GM-CSF, and other inflammatory markers in mice, demonstrating its potential to help manage conditions like multiple sclerosis. Who this helps: This helps patients with autoimmune diseases such as multiple sclerosis.

Plain English
This study looked at how drinking alcohol during pregnancy can lead to fetal alcohol spectrum disorders (FASD), which have serious and lasting effects on behavior and brain function. Researchers found that alcohol triggers changes in the brain's immune cells, leading to inflammation and affecting how brain cells survive and function. These changes can result in cognitive problems and brain damage that persist throughout a person's life, highlighting the need for new treatments that target inflammation to help prevent or address FASD. Who this helps: This helps patients with FASD and their families, as well as doctors seeking better treatments.

Plain English
This study looked at how a natural compound called β-lapachone, derived from the lapacho tree, affects a model of multiple sclerosis (MS), an autoimmune disease. The researchers found that β-lapachone reduced the levels of certain inflammatory markers and helped lessen the symptoms of the disease in a lab setting, showing a significant decrease in the production of harmful immune cells. This is important because it suggests that β-lapachone could be a new treatment option for inflammatory diseases like MS. Who this helps: This helps patients with multiple sclerosis and similar inflammatory conditions.

Plain English
This study looked at how alcohol affects the immune response in the brains of older mice. Researchers found that after giving the mice a dose of alcohol, there was a significant increase in a specific immune signal in the hippocampus and cerebellum, but not in the cortex. This suggests that different areas of the brain respond differently to alcohol, which is important because it may explain some of the health issues and addiction problems older people face with alcohol. Who this helps: This helps elderly patients and their healthcare providers understand the risks of alcohol use.

Plain English
This paper looks at Fetal Alcohol Spectrum Disorder (FASD), which occurs when pregnant women drink alcohol, leading to serious health issues for their children. It reviews how alcohol affects the brain and immune system's development, particularly focusing on certain brain cells (microglial cells) that help keep the brain working normally. The study highlights the need for new treatments that could involve immune system therapies to help children with FASD and notes the importance of understanding these mechanisms for future research. Who this helps: This helps patients with FASD and their families, as well as healthcare providers working to treat them.

Plain English
This study looked at how mitoxantrone, a treatment for multiple sclerosis (MS), affects certain brain cells called astrocytes. The researchers found that mitoxantrone reduces the production of harmful substances from these cells, such as nitric oxide and various inflammatory proteins, which are associated with MS. This is important because it reveals a possible way that mitoxantrone could help lessen the damage caused by inflammation in the brains of MS patients. Who this helps: This helps multiple sclerosis patients by potentially reducing inflammation-related damage in their brains.

Plain English
The study examined how resveratrol, a compound found in red grapes, affects the function of astrocytes, which are supportive cells in the brain, during inflammation related to diseases like Parkinson's and Alzheimer's. Researchers found that resveratrol reduced the production of several inflammatory substances in mouse astrocytes, including nitric oxide and various cytokines, which are linked to the immune response. This work matters because it shows that resveratrol may help combat inflammation in the brain, potentially offering a new treatment approach for neurodegenerative diseases. Who this helps: Patients with neurodegenerative diseases.

Plain English
This study looked at how ethanol (alcohol) exposure affects brain development in young mice and found that it harms important brain cells called Purkinje cells and microglia. Researchers discovered that a specific treatment with PPAR-γ agonists (a type of medication) helps protect these brain cells from the damaging effects of alcohol. This finding is important because it could lead to new treatments for preventing the severe brain damage caused by fetal alcohol exposure. Who this helps: This benefits patients with fetal alcohol spectrum disorders and their families.

Plain English
This study focused on a new compound called SR1001, which helps prevent the creation and function of a type of immune cell known as T(H)17 cells that are linked to autoimmune diseases. Researchers found that SR1001 was able to significantly reduce T(H)17 cell activity in laboratory mice and lessened the symptoms of autoimmune diseases in these animals. This discovery is important because it offers a potential new way to treat conditions like multiple sclerosis or rheumatoid arthritis by targeting the specific pathways involved in T(H)17 cell function. Who this helps: This helps patients with autoimmune diseases and their doctors.

Plain English
This study looked at how a drug called gemfibrozil, known as a PPAR-alpha agonist, helps protect mice from a disease similar to multiple sclerosis. Researchers found that gemfibrozil changes the immune response by increasing the activity of a certain protein (GATA-3) while reducing another (T-bet). This shift in immune response helps lessen the effects of the disease, indicating that PPAR-alpha agonists could be a promising treatment for autoimmune conditions. Who this helps: Patients with autoimmune diseases like multiple sclerosis.

Plain English
This research studied how a drug called LXR agonist T0901317 affects certain immune cells (Th17 cells) linked to autoimmune diseases like multiple sclerosis (MS). The researchers found that T0901317 reduced the production of a harmful protein (IL-17A) and also blocked other signals that drive the immune response in mice models. This matters because it suggests that LXR agonists could be a promising treatment for preventing or reducing symptoms of MS. Who this helps: This benefits patients with multiple sclerosis and possibly other autoimmune disorders.

Plain English
This study looks at the role of Toll-like receptors (TLRs) in multiple sclerosis (MS), a disease affecting the central nervous system that involves inflammation and damage to nerve cells. Researchers found that TLRs, which help the immune system recognize pathogens, may significantly influence the progression of MS and a related animal model, showing that targeting these receptors could provide new insights into treatment strategies. Understanding how TLRs affect MS is important for developing better therapies for this chronic illness. Who this helps: This helps patients with multiple sclerosis and doctors treating them.

Plain English
This study focuses on a group of proteins called PPAR-gamma, which are important in regulating metabolism and the immune system. Researchers found that drugs that activate PPAR-gamma may help manage multiple sclerosis, shown in animal models where these drugs influenced disease development. This is significant because it opens up new possibilities for treating MS, a challenging condition that affects many people. Who this helps: Patients with multiple sclerosis.

Plain English
This study looked at how a specific drug, 15-deoxy-Delta-prostaglandin J(2), affects inflammation in the brain related to Alzheimer's disease. Researchers found that this drug reduced the levels of certain inflammatory substances (IL-12 and IL-23) that contribute to brain inflammation caused by the accumulation of amyloid-beta, a protein linked to Alzheimer's. This is important because reducing these levels could help improve treatments for Alzheimer's and lessen harmful brain inflammation. Who this helps: This helps patients with Alzheimer's disease and their doctors.

Plain English
This study looked at how a specific protein called PPAR-alpha affects the immune response, particularly in autoimmune diseases like multiple sclerosis. Researchers found that PPAR-alpha helps control the development of immune cells called T cells and that drugs activating PPAR-alpha improved symptoms in mice with a condition similar to multiple sclerosis. This matters because it shows potential new ways to treat autoimmune diseases in humans by targeting this protein. Who this helps: Patients with autoimmune diseases, especially those with multiple sclerosis.

Plain English
Researchers studied the effects of a drug called ciglitazone on brain abscesses caused by bacterial infections, specifically looking at how it influences inflammation and the body's response to these abscesses. They found that treating with ciglitazone reduced the number of bacteria and lessened harmful inflammation, helping to contain the infection better. Importantly, treatment also sped up the process of forming a protective barrier around the abscess, which is crucial for preventing further spread of the bacteria. Who this helps: This benefits patients with brain abscesses and their doctors by offering a potential new treatment option.

Plain English
This study focused on how certain compounds called LXR agonists affect brain cells involved in inflammation, specifically microglia and astrocytes. The researchers found that these LXR agonists reduced the production of harmful substances like nitric oxide and cytokines in these cells by interfering with specific signaling pathways, indicating a potential way to manage inflammation in diseases like multiple sclerosis. The results show that using LXR and RXR agonists together could enhance their anti-inflammatory effects. Who this helps: This benefits patients with neuroinflammatory diseases, particularly multiple sclerosis.

Plain English
This study looked at how certain drugs, known as PPAR-gamma agonists, affect the production of specific proteins called IL-12 family cytokines in brain cells related to multiple sclerosis (MS). The researchers found that these drugs significantly reduced the levels of several cytokines—specifically IL-12p40, IL-23, and IL-27—produced by brain cells when stimulated. This matters because it suggests that PPAR-gamma agonists could play an important role in treating MS by reducing harmful inflammation in the brain. Who this helps: This research benefits patients with multiple sclerosis.

Plain English
This study looked at how fenofibrate, a medication that activates a specific receptor in cells, affects certain proteins involved in inflammation in the brain related to multiple sclerosis (MS). Researchers found that fenofibrate reduced the production of pro-inflammatory proteins, known as cytokines, which are often elevated during MS. Specifically, the treatment led to lower levels of several cytokines, including IL-12 and IL-23, suggesting it may help control inflammation in the nervous system, which is important for managing MS symptoms and progression. Who this helps: Patients with multiple sclerosis.

Plain English
This study looked at how 9-cis-retinoic acid affects certain brain cells involved in inflammation, particularly in conditions like multiple sclerosis (MS). The researchers found that 9-cis-retinoic acid reduced harmful substances produced by these cells, such as nitric oxide and specific inflammatory proteins, which helps decrease inflammation in the brain. These findings are important because they indicate that this substance could be a potential treatment for MS. Who this helps: This helps patients with multiple sclerosis.

Plain English
This research studied how certain drugs called PPAR agonists could help treat multiple sclerosis (MS), a disease marked by inflammation in the nervous system. The researchers found that a specific PPAR agonist, 15-deoxy-Delta(12,14) prostaglandin J2, significantly reduced harmful T cells in a model of MS, leading to less disease activity. This is important because it opens the door to using well-tolerated medications already used for other health issues, like high triglycerides, to help MS patients manage their condition effectively. Who this helps: This benefits patients with multiple sclerosis.

Plain English
This study examined how certain drugs that activate peroxisome proliferator-activated receptors (PPARs) might influence the behavior of immune cells in the brain during inflammation. It found that these drugs can help manage the activation of microglia and astrocytes, which are brain cells that protect against illness but can become harmful when overly activated. This is important because chronic activation of these cells is linked to serious brain disorders like multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease. Who this helps: This helps patients with neuroinflammatory disorders and the doctors treating them.

Plain English
This study looked at how certain drugs, called PPAR-alpha agonists (specifically fenofibrate and gemfibrozil), affect a type of brain cell involved in multiple sclerosis (MS). The researchers found that these drugs significantly reduced the production of harmful substances like nitric oxide and inflammatory molecules in mouse brain cells when tested. This is important because it suggests a potential path for treating MS by targeting the inflammation caused by these brain cells. Who this helps: This benefits patients with multiple sclerosis by exploring new treatment options.

Plain English
This study examined two substances, 15d-PGJ2 and PGA2, to see how well they can reduce inflammation in certain brain cells (microglia and astrocytes) that are involved in multiple sclerosis (MS). The researchers found that both substances effectively reduced harmful substances produced by these brain cells, with 15d-PGJ2 being better at lowering one type of inflammation marker and PGA2 being more effective at reducing others. This is important because finding effective treatments for inflammation in the brain could help improve therapies for MS, a condition that affects many people. Who this helps: This helps patients with multiple sclerosis and their doctors.

Plain English
Researchers studied how certain drugs called PPAR-gamma agonists, specifically thiazolidinediones (like rosiglitazone and pioglitazone) and a compound called 15d-PGJ2, affect immune cells involved in inflammation in a mouse model of multiple sclerosis (MS). They found that all these compounds successfully reduced harmful substances produced by immune cells, like nitric oxide and cytokines, but 15d-PGJ2 was notably more effective in doing so than the thiazolidinediones. This is important because it suggests that these drugs could be beneficial in treating MS by reducing inflammation in the brain. Who this helps: This research helps patients with multiple sclerosis by identifying potential treatments that target inflammation.

Plain English
This study explored how certain hormones can influence the activity of microglial cells, which play a role in multiple sclerosis (MS). Researchers found that a compound called 15d-PGJ(2) is particularly effective at reducing harmful microglial activation, outpacing other treatments, and when combined with another substance called 9-cis retinoic acid, its effect is even stronger. This is important because controlling microglial activation could help protect the brain and improve outcomes for people with MS. Who this helps: This helps patients with multiple sclerosis and their doctors.

Plain English
This study looked at how certain drugs, called PPAR-alpha agonists and RXR agonists, affect microglial cells in mice, which are involved in inflammation related to multiple sclerosis (MS). The researchers found that these drugs significantly reduced the production of harmful compounds and inflammatory substances in microglia, with fenofibrate and another drug being the most effective. This is important because it suggests a potential new treatment approach for MS, which is characterized by excessive inflammation in the brain. Who this helps: Patients with multiple sclerosis.

Plain English
Researchers tested whether a natural substance called 15d-PGJ2 could reduce the harmful inflammation that brain cells called microglia create when fighting a common bacterial infection (Staphylococcus aureus). The substance successfully blocked many inflammatory signals that microglia release, which normally damage healthy brain tissue surrounding a brain abscess. This discovery suggests that 15d-PGJ2 could become a treatment that lets the immune system fight the infection while protecting the brain from collateral damage.